Recombinant Varicella Zoster Virus Glycoprotein E Antigen

The standard dosage for Recombinant Varicella Zoster Virus Glycoprotein E Antigen is a two-dose series. Each dose consists of 0.5 mL of the reconstituted suspension, which contains 50 micrograms of the recombinant antigen.

• First Dose: Administered at a date chosen by the patient and healthcare provider.
• Second Dose: Administered 2 to 6 months after the first dose.

For individuals who are or will be immunodeficient or immunosuppressed due to known disease or therapy and who would benefit from a shorter vaccination schedule, the second dose may be administered 1 to 2 months after the first dose. Clinical studies have shown that completing the two-dose series is essential for achieving the high levels of protection reported in medical literature. If more than 6 months have passed since the first dose, the second dose should still be administered as soon as possible; the series does not typically need to be restarted, though you should consult your doctor for specific guidance.

Recombinant Varicella Zoster Virus Glycoprotein E Antigen is NOT approved for use in children or adolescents under the age of 18. The safety and efficacy of this specific recombinant antigen have not been established in the pediatric population. Children requiring protection against chickenpox typically receive the live-attenuated varicella vaccine, which is a different product entirely. If a child is accidentally administered this antigen, parents should contact a pediatrician immediately for observation, although no specific toxicity is expected.

Renal Impairment

No dosage adjustments are required for patients with renal (kidney) impairment. Because the antigen is a protein that is metabolized by cellular proteolysis rather than renal filtration, kidney function does not affect the safety or efficacy of the vaccine. Clinical trials included patients with various degrees of renal dysfunction without identifying any unique safety concerns.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic (liver) impairment. The metabolism of recombinant proteins does not rely on the hepatic metabolic pathways used by traditional medications. Patients with chronic liver disease can safely receive this antigen provided they do not have other contraindications.

Elderly Patients

This antigen is specifically designed for elderly patients. No dose adjustment is necessary for patients aged 50 to 100+. In fact, clinical data shows that the immune response remains robust even in the oldest age cohorts (80+), which is a unique feature of this recombinant technology compared to older vaccines.

This medication is administered exclusively via intramuscular (IM) injection by a trained healthcare professional. It should never be administered intravenously, intradermally, or subcutaneously.

• Preparation: The healthcare provider will check the expiration date and ensure the lyophilized powder and the liquid adjuvant are at the correct temperature (refrigerated until use).
• Administration: The injection is usually given in the deltoid muscle of the upper arm. You should inform the provider which arm you prefer (typically the non-dominant arm).
• Storage: Before reconstitution, the vials must be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). They must be protected from light and should never be frozen. If the vaccine is frozen, it must be discarded.
• Post-Injection: You may be asked to wait in the clinic for 15 minutes after the injection to monitor for any immediate allergic reactions or fainting (syncope).

If you miss the window for your second dose (2 to 6 months after the first), you should schedule an appointment with your healthcare provider as soon as you remember. According to the Centers for Disease Control and Prevention (CDC), you do not need to restart the entire series if the second dose is delayed beyond 6 months; however, you are not fully protected until the second dose is completed. A single dose provides significantly less protection and a shorter duration of immunity than the full two-dose regimen.

Because this antigen is administered by healthcare professionals in a controlled clinical setting, the risk of an overdose is extremely low. An 'overdose' in the context of a vaccine would mean receiving more than the recommended 0.5 mL dose. In the rare event that an extra dose is administered, the most likely result would be an increase in the severity of local side effects, such as increased pain, swelling, or redness at the injection site. There is no specific 'antidote' for a vaccine overdose. Management involves treating the symptoms (e.g., using acetaminophen for pain or fever) and monitoring for any unusual systemic reactions.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip the second injection without medical guidance, as this will compromise your protection against shingles.

Recombinant Varicella Zoster Virus Glycoprotein E Antigen is known to be 'reactogenic,' meaning it commonly triggers a noticeable immune response. This is often a sign that the vaccine is working to build your defenses. More than 10% of recipients experience the following:

• Injection Site Pain: This is the most frequently reported side effect. It is typically described as a dull ache in the arm where the shot was given. It usually begins within a few hours of the injection and may last for 2 to 3 days.
• Myalgia (Muscle Pain): Many patients report generalized muscle aches throughout the body, similar to the feeling of having the flu.
• Fatigue: A feeling of significant tiredness or lack of energy is common as the body diverts resources to the immune response.
• Headache: Mild to moderate headaches are frequently reported in the first 48 hours.
• Shivering and Fever: Some recipients may experience chills or a low-grade fever (usually under 101°F).
• Gastrointestinal Symptoms: Nausea, vomiting, or diarrhea may occur in a significant number of patients.

These effects occur in 1% to 10% of individuals and are generally manageable:

• Injection Site Swelling and Redness: The area around the injection may become visibly red or swollen (erythema). This can sometimes extend several inches from the injection site.
• Malaise: A general feeling of being unwell or 'under the weather' that persists for a few days.
• Lymphadenopathy: Swelling of the lymph nodes, particularly in the armpit (axilla) on the side of the injection.

Rarely, patients may experience more unusual symptoms. These are documented in post-marketing surveillance:

• Hypersensitivity Reactions: This includes non-serious rashes or hives (urticaria).
• Syncope (Fainting): This is often a vasovagal response to the needle stick rather than a reaction to the antigen itself, but it is documented as a potential event following vaccination.
• Severe Local Reactions: In rare cases, the swelling at the injection site may be severe enough to limit the movement of the arm for several days.

While extremely rare, serious adverse events can occur. You must seek emergency medical care if you experience any of the following:

• Anaphylaxis: Signs of a severe allergic reaction include difficulty breathing, swelling of the face, tongue, or throat, a rapid heartbeat, and a severe rash or hives.
• Guillain-Barré Syndrome (GBS): This is a rare neurological disorder where the body's immune system attacks the nerves. Symptoms include tingling or weakness in the legs that spreads to the upper body, difficulty walking, or difficulty with facial movements. The FDA has noted a small increased risk of GBS (approximately 3 to 6 additional cases per million doses) in the weeks following vaccination with the finished product containing this antigen.
• High Fever: A fever exceeding 103°F (39.4°C) or a fever that does not respond to over-the-counter fever reducers.

> Warning: Stop taking Recombinant Varicella Zoster Virus Glycoprotein E Antigen and call your doctor immediately if you experience any signs of a severe allergic reaction or unusual neurological symptoms.

There are no known long-term 'toxic' side effects associated with Recombinant Varicella Zoster Virus Glycoprotein E Antigen. Unlike some medications that can cause cumulative damage to organs like the liver or kidneys, this antigen is a protein that is cleared from the body within days. The 'long-term' effect of this medication is intended to be positive: the persistence of antibodies and memory T-cells that protect against shingles for a decade or more. Clinical trials monitoring patients for up to 10 years have not identified any delayed-onset safety concerns.

There are currently no FDA black box warnings for Recombinant Varicella Zoster Virus Glycoprotein E Antigen. This indicates that the product has a favorable safety profile when used as directed in the appropriate populations. However, the lack of a black box warning does not mean the vaccine is without risk, and all patients should be screened for allergies before administration.

Report any unusual symptoms or side effects that persist for more than 72 hours to your healthcare provider. You or your doctor can also report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967.

Before receiving Recombinant Varicella Zoster Virus Glycoprotein E Antigen, it is essential to inform your healthcare provider of your complete medical history. While this antigen is generally safe, certain conditions may require caution or a delay in vaccination. If you are currently suffering from a moderate to severe acute illness, with or without a fever, your doctor will likely recommend waiting until you have recovered before receiving the injection. This ensures that the symptoms of your illness are not confused with side effects of the vaccine and that your immune system can focus entirely on responding to the antigen.

No FDA black box warnings for Recombinant Varicella Zoster Virus Glycoprotein E Antigen. This product has been extensively studied in tens of thousands of participants in clinical trials, showing a safety profile that the FDA deems acceptable for the prevention of shingles.

• Allergic Reactions / Anaphylaxis Risk: As with any injected protein, there is a risk of a severe allergic reaction. Your healthcare provider will ask if you have ever had a life-threatening reaction to any component of the vaccine, including the gE antigen or the substances used in the adjuvant (such as dioleoyl phosphatidylcholine). Facilities where the vaccine is administered must have appropriate medical treatment (like epinephrine) available in case of anaphylaxis.
• Immunosuppression: If you are receiving immunosuppressive therapy (such as high-dose steroids, chemotherapy, or radiation), the immune response to the antigen may be diminished. While it is safe for immunocompromised patients to receive this non-live vaccine, the level of protection achieved may be lower than that seen in healthy individuals. Your doctor will time the vaccination to maximize its effectiveness.
• Syncope (Fainting): Fainting can occur after any injection. To prevent injury from falls, you should remain seated or lying down for about 15 minutes after the procedure. If you have a history of fainting after needles, inform your provider beforehand.
• Thrombocytopenia and Coagulation Disorders: As the vaccine is given via intramuscular injection, patients with low platelet counts (thrombocytopenia) or bleeding disorders (like hemophilia) may experience significant bruising or bleeding at the injection site. The healthcare provider may use a fine needle and apply firm pressure for several minutes to minimize this risk.

There are no specific laboratory tests (like blood counts or liver function tests) required before or after receiving this antigen. Unlike chronic medications, this is a one-time (two-dose) intervention. However, patients who are severely immunocompromised may occasionally have their antibody levels checked by a specialist to confirm an immune response, although this is not standard practice for most people.

While the antigen itself does not cause sedation, some common side effects like fatigue, headache, or malaise could temporarily impair your ability to drive or operate heavy machinery safely. You should observe how you feel for the first 24 to 48 hours after vaccination before engaging in these activities.

There is no direct interaction between alcohol and Recombinant Varicella Zoster Virus Glycoprotein E Antigen. However, excessive alcohol consumption can suppress the immune system and may worsen some side effects like headache, nausea, or fatigue. It is generally advisable to avoid heavy drinking for a few days after vaccination to allow your body to recover.

Because this is a vaccine series and not a daily medication, 'discontinuation' refers to the decision not to receive the second dose. If you had a severe allergic reaction to the first dose, you must NOT receive the second dose. If you experienced common side effects like pain or fever, these are not reasons to discontinue the series; instead, discuss with your doctor how to manage these symptoms for the second dose (e.g., taking an analgesic beforehand).

> Important: Discuss all your medical conditions, including any history of autoimmune disease or previous vaccine reactions, with your healthcare provider before starting Recombinant Varicella Zoster Virus Glycoprotein E Antigen.

There are no specific drugs that are absolutely contraindicated for use with Recombinant Varicella Zoster Virus Glycoprotein E Antigen in the same way that certain drugs cannot be mixed with nitroglycerin or MAO inhibitors. However, the vaccine itself should NEVER be mixed in the same syringe with any other vaccine or medication. Each vaccine must be administered at a separate injection site using a separate syringe.

• Immunosuppressive Therapies: Drugs that significantly suppress the immune system can interfere with the body's ability to respond to the gE antigen. This includes high-dose corticosteroids (e.g., prednisone >20mg/day), TNF-inhibitors (e.g., adalimumab, etanercept), and chemotherapy agents. The interaction is not a 'toxic' one, but rather a 'functional' one where the vaccine becomes less effective. Healthcare providers often recommend vaccinating at least 2 to 4 weeks before starting immunosuppressive therapy if possible.
• Other Vaccines: While this antigen can be given at the same time as the inactivated influenza vaccine or the pneumococcal vaccine, doing so may slightly increase the intensity of side effects like fever or muscle aches. They should always be given in different arms.

• Antipyretics and Analgesics: Medications like acetaminophen (Tylenol) or ibuprofen (Advil) are often used to treat the side effects of the vaccine. While some studies in other vaccines suggested that taking these before the shot might slightly lower the initial immune response, current clinical guidelines for the gE antigen do not prohibit their use to manage discomfort after the injection.

There are no known interactions between Recombinant Varicella Zoster Virus Glycoprotein E Antigen and any foods, including grapefruit, dairy, or high-fat meals. Because the antigen is administered by injection and bypasses the digestive system, dietary choices do not affect its absorption or efficacy.

There is no documented evidence that herbal supplements like St. John's Wort, ginkgo biloba, or kava interact with this recombinant antigen. However, supplements that claim to 'boost' or 'alter' the immune system (like high-dose echinacea or elderberry) have not been studied in conjunction with this vaccine. It is best to maintain your usual routine and inform your doctor of all supplements you are taking.

• VZV Antibody Testing: Receiving this antigen will cause a positive result on certain Varicella Zoster Virus antibody tests (specifically those looking for IgG antibodies). This is the intended effect. However, if a doctor is trying to diagnose a current infection, they must use different diagnostic methods (like PCR swabs of a rash) because the antibody test will not be able to distinguish between vaccine-induced immunity and natural infection.
• Tuberculosis (TB) Testing: Some vaccines can cause temporary false-negative results on skin tests for tuberculosis (PPD). While this has not been specifically proven for the gE antigen, some clinicians prefer to perform TB skin testing either on the same day as vaccination or wait 4 to 6 weeks after vaccination to ensure accuracy.

For each major interaction, the mechanism is typically pharmacodynamic (affecting the body's response) rather than pharmacokinetic (affecting drug levels). The management strategy is usually timing-based—ensuring the vaccine is given when the immune system is most capable of responding.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you are undergoing treatment for cancer or an autoimmune disorder.

There are two primary absolute contraindications for Recombinant Varicella Zoster Virus Glycoprotein E Antigen. In these cases, the vaccine must NEVER be administered because the risk of a life-threatening reaction is too high:

1. 1Severe Allergic Reaction (Anaphylaxis) to a Previous Dose: If an individual experienced a severe, immediate allergic reaction after the first dose of the vaccine containing this antigen, they must not receive the second dose. The mechanism is an IgE-mediated hypersensitivity where the immune system overreacts to the protein, causing airway constriction and low blood pressure.
2. 2Severe Allergic Reaction to Any Component of the Vaccine: This includes a known allergy to the gE antigen itself or any of the excipients, such as the adjuvant components or the polysorbate 80 used in the formulation.

Relative contraindications require a careful risk-benefit analysis by a healthcare professional. Vaccination may be delayed or performed under closer supervision in the following scenarios:

• Acute Febrile Illness: If a patient has a high fever or a significant infection (like pneumonia or a severe UTI), vaccination is usually postponed. The mechanism is to avoid 'masking' the symptoms of the illness or attributing vaccine side effects to the underlying disease.
• Pregnancy: While not an absolute contraindication, there is limited data on the use of this recombinant antigen in pregnant women. Most providers will delay vaccination until after delivery unless the risk of shingles is exceptionally high.
• Current Shingles Outbreak: The vaccine is not intended to treat an active case of shingles. It is generally recommended to wait until the rash has completely disappeared before administering the antigen to prevent shingles in the future.

There is no known cross-sensitivity between this recombinant antigen and the older live-attenuated shingles vaccine (Zostavax). Patients who had a reaction to the older vaccine may still be able to receive this recombinant version, as the ingredients (especially the lack of live virus and the different adjuvant) are distinct. However, a history of any vaccine-related anaphylaxis should be discussed with an allergist.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of 'anaphylactoid' reactions, before prescribing or administering Recombinant Varicella Zoster Virus Glycoprotein E Antigen.

Recombinant Varicella Zoster Virus Glycoprotein E Antigen is classified as a product where human data are insufficient to establish whether there is a vaccine-associated risk in pregnancy. Animal studies (using rats) have shown no evidence of harm to the fetus or problems with fertility. However, because shingles is not typically an emergency condition, most healthcare providers recommend delaying the vaccination series until after pregnancy. There is no known risk to using this antigen in women who are planning to become pregnant or who are undergoing fertility treatments.

It is not known whether the recombinant gE antigen or the antibodies triggered by the vaccine are excreted in human milk. However, because the antigen is a non-live protein and is administered in a very small dose (50 mcg), it is highly unlikely to pose a risk to a nursing infant. The decision to vaccinate a breastfeeding mother should take into account the mother's risk of shingles and the benefits of breastfeeding for the infant. The CDC generally considers non-live vaccines to be safe for breastfeeding women.

This antigen is not approved for use in individuals under 18 years of age. The primary reason is that the disease it prevents—shingles—is relatively rare in children with healthy immune systems. Furthermore, the safety and efficacy have not been tested in this age group. Children should follow the standard pediatric immunization schedule, which includes the varicella (chickenpox) vaccine.

The geriatric population is the primary group for which this antigen was developed. Clinical trials included thousands of participants over the age of 65, 75, and 85.

• Efficacy: Unlike many other vaccines, the efficacy of this recombinant antigen remains remarkably high (over 90%) even in the very elderly.
• Safety: While older adults may have more underlying health conditions (polypharmacy), there was no evidence that the vaccine was less safe for them. However, providers should be mindful of the risk of syncope (fainting) and the potential for local side effects to cause temporary discomfort in frail patients.

Patients with renal impairment, including those on dialysis, can receive this antigen. There is no evidence that reduced kidney function alters the body's immune response to the gE protein. No dose adjustments are necessary for any stage of chronic kidney disease (CKD).

Similarly, hepatic impairment does not affect the safety or efficacy of this antigen. The liver is not involved in the 'clearance' of the vaccine in a way that would require dose modification. Patients with cirrhosis or other liver diseases can be vaccinated according to the standard schedule.

> Important: Special populations, particularly those with complex medical histories or multiple prescriptions, require an individualized medical assessment by a qualified healthcare provider.

Recombinant Varicella Zoster Virus Glycoprotein E Antigen works by inducing a targeted immune response against the Varicella Zoster Virus (VZV). The Glycoprotein E (gE) is a type I transmembrane protein and is the most prominent glycoprotein on the surface of the VZV virion and in the membranes of infected cells. It plays a critical role in viral cell-to-cell spread and skin secondary infection.

By introducing the purified gE protein into the body, the vaccine bypasses the need for a live virus. The antigen is combined with the AS01B adjuvant system, which consists of MPL (3-O-desacyl-4’-monophosphoryl lipid A) and QS-21 (a purified saponin fraction). The MPL activates the TLR4 (Toll-like receptor 4) signaling pathway, while QS-21 stimulates the subcapsular sinus macrophages. Together, they enhance the recruitment of antigen-presenting cells to the injection site, leading to a much stronger and more durable production of gE-specific CD4+ T-cells and neutralizing antibodies than the antigen could achieve alone.

The pharmacodynamic effect of this antigen is measured by 'immunogenicity'—the ability to provoke an immune response.

• Onset: A measurable increase in antibodies is seen after the first dose, but the full protective effect is only reached approximately 4 weeks after the second dose.
• Duration: Data suggests that the protective immune response (both humoral and cellular) persists for at least 10 years, with mathematical models suggesting protection may last much longer.
• Tolerance: There is no evidence of the body developing 'tolerance' to the vaccine; rather, the second dose acts as a 'booster' to solidify the memory of the immune system.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular injection) |

| Protein Binding | N/A (Acts as an antigen, not a systemic drug) |

| Half-life | Days (Protein catabolism) |

| Tmax | N/A (Immune response peaks at ~4 weeks post-series) |

| Metabolism | Cellular proteolysis (Lysosomal degradation) |

| Excretion | Not renally or fecally excreted in significant form |

• Molecular Formula: C₂₂₄₅H₃₄₉₆N₆₁₄O₆₉₀S₁₇ (Approximate for the gE protein sequence)
• Molecular Weight: Approximately 50-60 kDa (kilodaltons) for the truncated gE protein used in the vaccine.
• Solubility: Soluble in aqueous buffers after reconstitution.
• Structure: The antigen is a truncated version of the native VZV gE protein, consisting of the extracellular domain without the hydrophobic transmembrane and cytoplasmic tail sequences. It is produced via recombinant DNA technology in Chinese Hamster Ovary (CHO) cells.

Recombinant Varicella Zoster Virus Glycoprotein E Antigen is classified as a Recombinant Subunit Vaccine. It is distinct from live-attenuated vaccines (like the original chickenpox vaccine) and mRNA vaccines. It belongs to the broader therapeutic category of Immunologicals / Vaccines.